This is a summary of dosing regimens reported in published clinical trials — what scientists have tested, not a recommendation for any individual's use. Geroevidence does not provide dosing guidance; consult a licensed physician for any clinical decision.
This article reports what specific published trials tested in their study protocols. It is historical and descriptive — it does not constitute a dosing recommendation, clinical guidance, or treatment protocol. Rapamycin is not FDA-approved for longevity use, and any off-label use should only be undertaken under the supervision of a licensed physician evaluating an individual's specific health profile.
Rapamycin's FDA-approved indication — preventing organ transplant rejection — uses continuous daily dosing to maintain constant immunosuppression. Longevity-context research has generally tested a different approach: intermittent, lower-dose regimens, based on the hypothesis (not yet definitively confirmed in long-term human outcome data) that intermittent dosing may achieve geroprotective mTOR inhibition while reducing the immunosuppressive burden of continuous dosing.
The PEARL trial (Mannick et al., published in Science Translational Medicine, 2024) studied weekly low-dose rapamycin in healthy older adults, evaluating immune function markers rather than a hard mortality outcome. This reflects a broader pattern across the current published trial base: most longevity-context human studies have used weekly or intermittent regimens rather than the daily dosing seen in transplant medicine, and have measured surrogate or biomarker endpoints rather than long-term clinical outcomes.
No published trial has established an optimal dose, frequency, or duration for longevity purposes in healthy adults — "optimal" implies a validated outcome trial comparing regimens, which doesn't yet exist for this use case. Long-term safety data specific to low-dose, intermittent protocols in healthy (non-transplant) populations is more limited than the decades of safety data behind the approved transplant indication. Reported effects in transplant-dose use include infection risk, mouth ulcers (stomatitis), and lipid changes; how these translate to lower, intermittent longevity-context dosing is an active research question, not a closed one.
Published trials describe what has been tested in a research context — they are not a substitute for individualized clinical judgment, and Geroevidence does not convert trial protocols into dosing recommendations for any reader. Anyone considering off-label rapamycin use should discuss it directly with a licensed physician familiar with their full medical history.